Research Advances on Prophylactic Anticoagulant Therapy for Primary Membranous Nephropathy
10.3870/j.issn.1004-0781.2024.03.016
- VernacularTitle:原发性膜性肾病预防性抗凝治疗研究进展
- Author:
Lian LI
1
;
Xingyue ZHENG
;
Liuyun WU
;
Qinan YIN
;
Lizhu HAN
;
Yang LEI
;
Yuan BIAN
Author Information
1. 电子科技大学医学院,成都 610054
- Keywords:
Primary membranous nephropathy;
Thromboembolism;
Preventive anticoagulation;
Serum albumin
- From:
Herald of Medicine
2024;43(3):418-423
- CountryChina
- Language:Chinese
-
Abstract:
Patients with primary membranous nephropathy(PMN)tend to develop thrombosis,especially in the early phase of the disease.The pathogenesis of thrombosis is multifactorial,with hypoalbuminemia being widely regarded as an inde-pendent risk factor.Other factors include proteinuria,M-type phospholipase A2 receptor antibody,and D-dimer.Although prophy-lactic anticoagulation therapy is frequently used in clinical practice to prevent thrombosis in PMN patients,there are still many un-resolved issues regarding the optimal prevention of thrombosis in this condition.The timing of prophylactic anticoagulation,the threshold of serum albumin level,and the choice of treatment regimen are still lacking consensus.This article reviewed the relevant literature on these topics,aiming to establish a standard for thrombosis prevention and treatment for this population in the future and provide guidance for clinical practice.
